| 2009-03-13: |
Xeloda use Associated With Better Re - Growth of Hair in Women With Breast Cancer
Zurich ( PRN/ots ) - - Hair Recovery was Quicker Following new Xeloda - Containing Chemotherapy Regimen - For Non - US Domestic Media Only Poster nos: 0145. First Safety Data from a Randomised Phase III Trial Comparing Adjuvant Epirubicin - Cyclophosphamide followed by Docetaxel ( EC followed by T ) (...) |
| 2009-03-11: |
European Commission Approves ReFacto AF( TM ) as a Variation to the Refacto( R ) Marketing Authorisation
Maidenhead, England ( PRN/ots ) - - Improvements in Purification Process Represent Important Advance in the Treatment of Haemophilia A Wyeth announced today it has received a positive decision from the European Commission for a variation of the marketing authorisation for ReFacto moroctocog alfa ( Recombinant (...) |
| 2009-03-11: |
Agendia Presents Data Supporting MammaPrint's Predictive and Prognostic Power at 2009 St. Gallen Breast Cancer Conference
HUNTINGTON BEACH, California, and AMSTERDAM, The Netherlands, March 11 ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced that leading researchers from Agendia and the Netherlands Cancer Institute will present data from multiple studies at the 2009 St.Gallen Breast Cancer Conference. (...) |
| 2009-03-10: |
Chronic Kidney Disease and Hypertension: Twin Challenges for 21st Century Europe
Strasbourg, France ( PRN/ots ) - - Meeting at European Parliament relays stark message and calls for action to support early identification and treatment of CKD, especially among patients at greatest risk The European Kidney Health Alliance ( EKHA ) and World Kidney Day ( WKD ) organisations today (...) |
| 2009-03-10: |
Tolerx Expands Phase 3 'DEFEND' Trial of Otelixizumab in Europe
Cambridge, Massachusetts ( PRN/ots ) - Tolerx, Inc., today announced that DEFEND ( Durable Response Therapy Evaluation For Early or New Onset Type 1 Diabetes ), the Phase 3 trial of otelixizumab, an investigational novel targeted immunotherapeutic, has begun enrollment of new onset autoimmune type 1 diabetes (...) |
| 2009-03-02: |
Wyeth's 7 - valent Vaccine for Pneumococcal Disease Registered in Russia
Maidenhead, England ( PRN/ots ) - - Prevenar Vaccine Helps Protect Against Leading Vaccine - Preventable Cause of Death in Young Children Worldwide Wyeth announced today that its 7 - valent pneumococcal conjugate vaccine, Prevenar( TM ) ( Pneumococcal saccharide conjugated vaccine, Adsorbed ), has been registered by the Russian Ministry (...) |
| 2009-02-19: |
CONBRIZA Receives Positive CHMP Opinion for the Treatment of Postmenopausal Osteoporosis in Women at Increased Risk of Fracture
Collegeville, Pennsylvania ( PRN/ots ) - The Committee for Medicinal Products for Human Use ( CHMP ), the scientific committee of the European Medicines Agency ( EMEA ), today adopted a positive opinion recommending to grant a marketing authorization for CONBRIZA( TM ) ( bazedoxifene ) for the treatment of postmenopausal osteoporosis in (...) |
| 2009-02-19: |
CRESTOR Cuts Risk of Stroke by Nearly Half in JUPITER Study
San Diego, California ( PRN/ots ) - A new analysis from the JUPITER study presented today at the International Stroke Conference ( ISC ) in San Diego, California, describes details of the stroke data according to gender, ethnicity and baseline risk factors. This data adds to the primary (...) |
| 2009-02-18: |
Agendia Publishes Direct Evidence That MammaPrint Predicts Benefit of Chemotherapy in Breast Cancer
Huntington Beach, California, and Amsterdam ( PRN/ots ) - - - Findings Published in Peer - Reviewed Journal, Breast Cancer Research and Treatment Agendia, a world leader in molecular cancer diagnostics, today announced that a study demonstrating the direct predictive ability of its breast cancer recurrence test, (...) |
| 2009-02-18: |
Video: The MDS Foundation Says Published Data Confirms VIDAZA( R ) Significantly Extends Survival in Patients with the Malignant Condition MDS
Crosswicks, New Jersey ( PRN/ots ) - - VIDAZA Restores Gene Function to Double Survival and Increase Transfusion Independence The Myelodysplastic Syndromes ( MDS ) Foundation says data published in the peer reviewed medical journal The Lancet Oncology confirms VIDAZA extends survival for patients with higher - risk (...) |
| 2009-02-18: |
Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
Lyon, France ( PRN/ots ) - - Global Clinical Study Program Across Dengue Endemic Regions in Latin America and Asia Sanofi Pasteur, the vaccines division of sanofi - aventis Group ( EURONEXT : SAN and NYSE : SNY ), announced today that its investigational tetravalent dengue vaccine is entering into (...) |
| 2009-02-17: |
Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
Lyon, France ( PRN/ots ) - - Novel Vaccine Approach Tested in the UK Against One of the Most Common Causes of Hospital - Acquired Infection in Europe and North America Sanofi Pasteur, the vaccines division of sanofi - aventis Group ( EURONEXT : SAN et NYSE : SNY ), announced (...) |
| 2009-02-16: |
For the First Time, Doctors can Predict Which Hepatitis B Patients Have the Highest Chance to Achieve Treatment Success With Pegasys( R )
Basel, Switzerland ( PRN/ots ) - - Immune - Boosting Effect of Pegasys Provides Patients With the Chance for a Clinical Cure FOR NON - UK MEDIA New data presented today showed that, for the first time, doctors can predict which hepatitis B patients treated with (...) |
| 2009-02-13: |
Study Proves Longer Prophylactic Therapy With Valcyte Increases Protection Against CMV - the Most Serious Viral Infection Affecting Transplant Patients
Basel, Switzerland ( PRN/ots ) - - Doubling Duration of Valcyte Therapy Provides Significant Benefit to Patients Compared to Current Standard of Care - For Non - US Media Only Roche announced today that a Phase III study investigating the efficacy and safety of extended preventative (...) |
| 2009-02-12: |
New England Journal of Medicine Publishes Results From the Landmark ATHENA Trial With Multaq( R ) ( dronedarone ) in Atrial Fibrillation
Paris ( PRN/ots ) - - Multaq( R ) ( dronedarone ) Significantly Reduced the Risk of Cardiovascular Hospitalization or Death by 24 Percent in Patients With Atrial Fibrillation Sanofi - aventis ( Paris Bourse: EURONEXT: SAN; and New York: NYSE: SNY ) announced today that the ATHENA trial was published (...) |
| 2009-02-07: |
Nplate( R ) Approved in the European Union for the Treatment of Chronic Immune ( Idiopathic ) Thrombocytopenic Purpura ( ITP )
Zug, Switzerland ( PRN/ots ) - - First and Only Approved Platelet Producer in Europe Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen ( Nasdaq: AMGN ) today announced that the European Commission ( EC ) has granted marketing authorisation for Nplate( R ) ( romiplostim ) for the treatment of (...) |
| 2009-02-04: |
Agendia's Breast Cancer Test MammaPrint( R ) Standard of Care at Netherlands Cancer Institute - AVL
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced that its signature breast cancer test MammaPrint( R ) will be offered as standard of care for all eligible early stage breast cancer patients at the Netherlands Cancer (...) |
| 2009-02-03: |
Cambridge Cognition Welcomes the Launch of the First National Dementia Strategy
Cambridge, England ( PRN/ots ) - - UK Strategy Underlines the Importance of Early Detection in the Care of Dementia and Alzheimer's Patients Cambridge Cognition Ltd, developers of a clinical diagnostic product that provides early warning of neurodegenerative conditions including Alzheimer's, welcomes the launch of (...) |
| 2009-02-03: |
Pieris reports development progress for Anticalin® PRS - 050, a next generation VEGF antagonist / Expansion of management team announced to support program success
Freising - Weihenstephan, Germany ( na Originaltextservice ) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, reports today that it has made significant progress in the development of its Anticalin® candidate PRS - 050, a potent VEGF antagonist (...) |
| 2009-01-30: |
ECASS 3 Study Receives Recognition From the European Stroke Organisation and The Lancet
Ingelheim, Germany ( PRN/ots ) - - ESO Recommends Extended Time Window for Actilyse( R ) INGELHEIM, Germany, January 30 /PRNewswire/ - - - For Healthcare Media outside the U.S.A., Canada, and Japan Based on key results from the European Cooperative Acute Stroke Study ( ECASS 3 ), the European (...) |
| 2009-01-29: |
AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages
Minneapolis ( PRN/ots ) - AGA Medical Corporation ( AGA ) today announced that, following its previously announced favorable patent infringement final ruling by the German court of appeals over Occlutech GmbH of Jena, Germany ( Occlutech ), it has calculated and notified Occlutech of the amount of damages (...) |
| 2009-01-13: |
The Turkish Government Adds Wyeth's 7 - valent Pneumococcal Conjugate Vaccine ( PCV7 ) to Their National Immunisation Schedule
Maidenhead, England ( PRN/ots ) - - Prevenar Vaccine to Help Protect Children Against the Leading Vaccine - Preventable Cause of Death in Young Children Worldwide Turkey has initiated a national immunization programme ( NIP ) against pneumococcal disease with Wyeth's Prevenar( TM ) ( Pneumococcal saccharide conjugated vaccine, Adsorbed ) - a (...) |
| 2009-01-06: |
MedImmune Submits Marketing Authorisation Application in European Union for Intranasal Vaccine to Prevent Seasonal Influenza
Nijmegen, The Netherlands ( PRN/ots ) - MedImmune, the global biologics unit of AstraZeneca, announced today that it has submitted a Marketing Authorisation Application ( MAA ) for its nasal spray live attenuated influenza vaccine ( LAIV ), which is now being reviewed by the European Medicines Agency (...) |
| 2009-01-06: |
German Appeals Court Rules in Favor of AGA Medical in Patent Infringement Lawsuit Against Occlutech
Minneapolis ( PRN/ots ) - AGA Medical Holdings, Inc. ( "AGA Medical" or "AGA" ) announced today that a German appeals court has ruled in its favor in a patent infringement proceeding against Occlutech GmbH, headquartered in Jena, Germany. The lawsuit was brought by AGA in (...) |
| 2008-12-31: |
Kidneys for Transplant Function Earlier and Last Longer When Preserved in a Machine Compared to the Traditional Box of Ice
Groningen, The Netherlands ( PRN/ots ) - Results from a landmark trial published today in the New England Journal of Medicine, show that in transplanted kidneys preserved and transported in a specially designed machine ( LifePort Kidney Transporter ) the odds for experiencing a delay in recovery of (...) |
| 2008-12-31: |
Study Shows Machine Perfusion Significantly Improves Transplant Results
Chicago, Illinois ( PRN/ots ) - A landmark study published today in the New England Journal of Medicine ( NEJM ) demonstrates that use of a specially designed machine to store kidneys for transplantation offers significant benefits in kidney survival and function when compared to those stored in (...) |
| 2008-12-18: |
Committee for Medicinal Products for Human Use ( CHMP ) Recommends Granting Marketing Authorisation for FIRMAGON( R ) ( degarelix ) for Treatment of Prostate Cancer
Saint Prex, Switzerland ( PRN/ots ) - - New Gonadotropin - Releasing Hormone ( GnRH ) Receptor Antagonist Demonstrates Rapid, Long - Term Suppression of Testosterone Ferring Pharmaceuticals received today notification that the Committee for Medicinal Products for Human Use ( CHMP ), part of the European Medicines Agency ( EMEA ), has (...) |
| 2008-12-15: |
Recruitment Ongoing in Europe for Two Tibotec Phase III Clinical Trials Studying TMC278 in Treatment - Naïve HIV - Infected Adults
Cork, Ireland ( PRN/ots ) - - Once - Daily TMC278 is the Third Anti - HIV Compound to be Developed in Tibotec Virology Portfolio Tibotec Pharmaceuticals is currently recruiting HIV - positive, treatment - naïve adults ( or those who have never taken antiretroviral medication before ) in Europe for (...) |
| 2008-12-14: |
Xeloda Shows Strong Promise in Early Breast Cancer
San Antonio, Texas ( PRN/ots ) - - FOR NON - US DOMESTIC and NON - UK journalists only - Early Data Indicate Chemotherapy Pill Xeloda, Already Proven in Advanced Breast Cancer, May Also Reduce Recurrence of Early Breast Cancer Data presented today indicate that adding Xeloda (...) |
| 2008-12-13: |
Agendia's Breast Cancer Test MammaPrint( R ) Identifies New Subset of Low Risk HER2+ Patients
Huntington Beach, California and Amsterdam ( PRN/ots ) - - - Recent Study Reveals Substantial Group of Traditionally Miscategorized HER2+ Patients Dr. Michael Knauer from the Netherlands Cancer Institute today announced data uncovering a substantial group of traditionally miscategorized low risk HER2+ patients. Agendia's highly accurate breast (...) |
| 2008-12-12: |
Agendia's MammaPrint( R ) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
Huntington Beach, California and Amsterdam ( PRN/ots ) - - Agendia, a world leader in molecular cancer diagnostics, today announced MammaPrint( R )'s ability to predict response to neoadjuvant chemotherapy in breast cancer. Dr. Laura van 't Veer, from the Netherlands Cancer Institute, presented the data at the (...) |
| 2008-12-09: |
MabThera Maintenance Therapy Helps Non - Hodgkin's Lymphoma Patients Live for Years Longer Without Their Disease Progressing
Basel, Switzerland ( PRN/ots ) - - For non - US and non - UK Media Only - Long - term Results From a Phase III Study Highlight the Beneficial Role of MabThera in Patients With Recurrent or Resistant Disease Data presented at the 50th Annual Meeting of (...) |
| 2008-12-09: |
VELCADE( R ) ( bortezomib ) Findings Reinforce Efficacy and Survival Across Multiple Patient Populations
Beerse, Belgium ( PRN/ots ) - - Preliminary Phase II Re - treatment Results and two new Analyses From Phase III VISTA Presented at ASH Annual Meeting Janssen - Cilag today announced preliminary results from a prospective, international, multicenter, open - label, phase II study showing re - treatment (...) |
| 2008-12-07: |
MabThera Significantly Reduces Risk of Serious Bleeding in People With Life - Threatening Autoimmune Disorder
Basel, Switzerland ( PRN/ots ) - - For Non - US and Non - UK Media Only - Abstract Number: 1 - New Phase III Data Suggest Potential Role for MabThera in Treating Blood Disorder New data presented at the 50th Annual Meeting of the American Society of (...) |
| 2008-12-06: |
New Data From Largest - Ever Clinical Trials in CLL Show MabThera Enables Leukaemia Patients to Live Longer Without Their Disease Progressing
Basel, Switzerland ( PRN/ots ) - - For Non - US and Non - UK Media BASEL, Switzerland, December 6 /PRNewswire/ - - - Abstract Numbers: 325 & LBA - 1 BASEL, Switzerland, December 6 /PRNewswire/ - - - Pivotal Phase III Results Suggest MabThera is Set to Change the Face of (...) |
| 2008-12-04: |
Results From the First and Largest Collaborative Study Confirm Role of Enbrel( R ) in Psoriatic Arthritis
Maidenhead, England ( PRN/ots ) - - New Data Add to the Body of Evidence That Show That Enbrel ( Etanercept ) Clears Skin and Can Sustain This Efficacy Over Time New data presented today at the 'Gene to Clinic' meeting taking place at the Royal (...) |
| 2008-12-04: |
European Commission Approval of New Indication for Roche's Pegasys( R ) ( peginterferon alfa - 2a ) Offers Hepatitis C Patients a Second Chance for a Cure
Basel ( PRN/ots ) - - Pegasys is the First and Only Pegylated Interferon to be Approved for Treatment of up to 72 Weeks in Treatment - Experienced Patients Roche announced today that the European Commission has approved Pegasys( R ) ( peginterferon alfa - 2a ( 0 KD ) ) plus Copegus( R ) (...) |
| 2008-12-03: |
Wyeth Submits European Marketing Authorization Application for its 13 - Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children
Collegeville, Pennsylvania ( PRN/ots ) - - Approval sought for investigational vaccine for protection against the 13 most prevalent serotypes associated with serious pneumococcal disease Wyeth Pharmaceuticals, a division of Wyeth ( NYSE: WYE ), announced today that it has submitted a marketing authorization application ( MAA ) to the (...) |
| 2008-12-03: |
PREZISTA( R ) ( darunavir ) Receives Expanded Marketing Authorisation in the European Union for Treatment - Experienced Adults With HIV - 1
Cork, Ireland ( PRN/ots ) - - For Medical Media Only - PREZISTA now Indicated for the Broad Range of Treatment - Experienced Patients in the 27 EU Member States Tibotec Pharmaceuticals announced today that the European Commission adopted the decision to broaden the indication for PREZISTA( R ) (...) |
| 2008-11-27: |
European Committee for Human Medicinal Products ( CHMP ) Issues Positive Opinion for Once - Daily PREZISTA( R ) ( Darunavir ) as Part of Combination Therapy for Treatment - Naïve Adults With HIV - 1
Cork, Ireland, November 27 ( PRN/ots ) - The Committee for Human Medicinal Products ( CHMP ) has issued a positive opinion recommending approval for once - daily dosing of 800 mg PREZISTA( R ) ( darunavir ) with low - dose ritonavir as part of combination therapy in treatment - naïve adults ( those who (...) |
| 2008-11-27: |
Bacardi Limited Offers "Driving Experience of a Lifetime" With F1( TM ) Legend Michael Schumacher
Hamilton, Bermuda, November 27 ( PRN/ots ) - - Schumacher - The Ultimate Designated Driver - Promotes Drinking and Driving Don't Mix at http://www.championsdrinkresponsibly.com Bacardi Limited, as part of its responsible drinking "Champions Drink Responsibly" campaign, is providing the drive of a lifetime - the opportunity (...) |
| 2008-11-21: |
New Antibiotic Against Serious Infections
Beerse, Belgium, November 21 ( PRN/ots ) - - European Authority Recommends Approval of ZEVTERA( TM ) BEERSE, Belgium, November 21 /PRNewswire/ - - - A Broad - spectrum, Anti - MRSA Cephalosporin Antibiotic to Treat Complicated Skin and Soft Tissue Infections BEERSE, Belgium, November 21 /PRNewswire/ - - The Committee for (...) |
| 2008-11-21: |
Nplate( TM ) ( Romiplostim ) Receives Positive Opinion for Marketing Authorisation in the European Union
Thousand Oaks, California, November 21 ( PRN/ots ) - - First and Only Approved Platelet Producer Represents New Treatment Approach for Serious Chronic Autoimmune Disorder Amgen ( Nasdaq: AMGN ) today announced that the European Committee for Medicinal Products for Human Use ( CHMP ) has issued a (...) |
| 2008-11-21: |
CHMP Recommends Approval of New Indication for Enbrel( R ) as Treatment for Severe Psoriasis in Paediatric Patients
Maidenhead, England, November 21 ( PRN/ots ) - - Not for UK Journalists The European Committee for Medicinal Products for Human Use ( CHMP ) today announced its positive recommendation for the approval of Enbrel( R ) ( etanercept ) as a treatment for children aged 8 years and over and (...) |
| 2008-11-21: |
New Biologic Ustekinumab Receives Positive Opinion From European Regulatory Authority for the Treatment of Moderate to Severe Plaque Psoriasis
Beerse, Belgium, November 21 ( PRN/ots ) - Janssen - Cilag announced today that ustekinumab, the first in a new class of biologics, has received a positive opinion for the treatment of moderate to severe plaque psoriasis from the European Committee for Medical Products for Human Use (...) |
| 2008-11-20: |
Intel Announces its First Home Medical Device in the United Kingdom to Better Connect Clinicians With Patients
London, November 20 ( PRN/ots ) - - Intel( R ) Health Guide is the First Product in a Series Designed to Enable More Personalised Care Management for Chronic and Age - related Conditions Intel Corporation today announced the Intel( R ) Health Guide, a care management tool designed for (...) |
| 2008-11-20: |
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Cork, Ireland, November 20 ( PRN/ots ) - - Nearly 90 Percent of Patients Achieve Undetectable Viral Load in Phase IIa Trial Within 28 Days of Combined Treatment With Standard of Care New clinical data demonstrate the safety and antiviral activity of TMC435, an investigational (...) |
| 2008-11-20: |
Tibotec Begins Enrollment in Europe for Phase III Trial of Telaprevir in HCV Patients who Failed Prior Treatment
Cork, Ireland, November 20 ( PRN/ots ) - - Telaprevir Data Presented at AASLD Tibotec BVBA today announced that it has begun enrolling patients in its phase III study of telaprevir ( VX - 950 ), an investigational protease inhibitor ( PI ), in patients with chronic genotype 1 hepatitis (...) |
| 2008-11-17: |
Quest Diagnostics' Laboratory in India Accredited by Two Leading Laboratory Accrediting Organizations
Madison, New Jersey and Gurgaon, India, November 17 ( PRN/ots ) - - Less than one tenth of one percent of labs in India are CAP and NABL accredited - Quest Diagnostics' laboratory also becomes one of only five labs in India to achieve NGSP (...) |
|
| back...
1
2
3
4
5
6
7
8
9
10
11
more... |
